Johnson & Johnson打破了对Q4收入的预期,预计2025-2030年增长强劲。 Johnson & Johnson beats Q4 earnings expectations, projects strong growth for 2025-2030.

Johnson & Johnson(J&J)的第四季度收入超过了华尔街的预期,销售额增长5.3%,达225.2亿美元。 Johnson & Johnson (J&J) exceeded Wall Street expectations for its fourth-quarter earnings, with sales up 5.3% to $22.52 billion. 癌症药物销售,特别是Darzalex,猛增19%,为增长作出了重大贡献。 Cancer drug sales, particularly Darzalex, surged 19%, contributing significantly to the growth. J&J预测2025年销售额在909亿至917亿美元之间,预计2025-2030年的年复合增长率为5%-7%,不包括货币影响。 J&J projects 2025 sales between $90.9 billion and $91.7 billion and forecasts a 5%-7% compound annual growth rate for 2025-2030, excluding currency impacts.